Large animal studies have been utilized to define tolerance of normal
brain to irradiation and verify treatment planning programs with two r
ecently installed epithermal neutron beams. The normal brain tolerance
studies utilized two biological endpoints, magnetic resonance visible
damage only and neurologic signs progressing to death. The studies fo
cused on defining the proton RBE for the contaminant fast neutrons, an
d from nitrogen capture of thermal neutrons and boron capture reaction
biologic effect. The proton RBE was approximately 3.0 to 6.7, dependi
ng on whether a dose reduction factor for the low gamma dose rate was
employed. The microscopic distribution of the boron compounds, coupled
with the extremely short length of the fission fragments from thermal
neutron capture by B-10 yields an observed biologic effect much less
than would be expected from such high LET irradiation. This observed b
iologic effect, which is a product of the microdistribution of the bor
on atom and the relative biologic effect of the fission fragments has
been termed compound factor. The compound factor was based on the calc
ulated physical dose from the fission fragment in blood based on measu
red blood B-10 concentration. The approximate compound factor for BSH
was studied at the two institutions and it ranged from 0.27 to 0.55, d
epending on the site and the endpoint chosen. The mean compound factor
for BPA was only studied at one site and was found to be 1.1 for both
endpoints. The increase in the compound factor for BPA is in keeping
with previous calculations based on the differences in compound distri
bution. Results of these studies has helped the initiation of phase I
and phase II clinical trials at Brookhaven National Laboratory and the
planned European clinical trials at Petten, The Netherlands.